Alex Biese
Senior Editor at CURE Magazine
Senior Editor of MJH Life Sciences’ CURE, NLGJA Excellence in Journalism Award winner, musician, work in progress.
Articles
-
1 week ago |
curetoday.com | Alex Biese
A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment expected in September. Six patients are left to complete the 25-patient enrollment target of the trial, according to a news release from clinical-stage biopharmaceutical company NeOnc Technologies Holdings, Inc.
-
1 week ago |
curetoday.com | Alex Biese
With the recent approval by the U.S. Food and Drug Administration (FDA) of Cabometyx (cabozantinib) for the treatment of patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET), another treatment option has become available to patients, as Dr. Jennifer Chan explained to CURE.
-
1 week ago |
curetoday.com | Alex Biese
A phase 1 clinical trial is now open for enrollment to patients with high-grade neuroendocrine tumors to receive treatment with a combination of immunotherapy and what has been described in a news release as a tumor-busing oncolytic virus injected directly into a tumor. The trial was announced in a news release issued by the Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.
-
1 week ago |
curetoday.com | Alex Biese
A New Drug Application (NDA) has been submitted to the Food and Drug Administration for ziftomenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM 1) mutation. The submission of the application was announced in a news release issued by Kura Oncology, Inc., and Kyowa Kirin Co., Ltd., which described the investigational drug as a highly selective, once-daily, oral, investigational menin inhibitor.
-
1 week ago |
curetoday.com | Alex Biese
Use of the NeuroSAFE technique during prostate cancer surgery nearly doubled the number of patients who had no or mild erectile dysfunction approximately a year later, researchers have found.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 2K
- Tweets
- 11K
- DMs Open
- No
Did you know that 81% of cancer cures touted on #TikTok are fake? Find out more about this in my latest for @cure_today & @MJHLifeSciences: https://t.co/2njUslyayh
.@kaydaustin was diagnosed with a rare stage 4 cancer at the age of 29. She hopes her new book, “Too Young for Cancer,” inspires other patients to advocate for themselves. Learn more in my latest for @cure_today/@MJHLifeSciences https://t.co/B85fCDx9vA
#DaveCoulier has non-Hodgkin lymphoma. Here’s what we know so far about the news from the actor best known as Uncle Joey on #FullHouse: https://t.co/iD5pPwpwVJ @cure_today @MJHLifeSciences
